Adamas Pharmaceuticals (NASDAQ:ADMS) Given Buy Rating at HC Wainwright

HC Wainwright restated their buy rating on shares of Adamas Pharmaceuticals (NASDAQ:ADMS) in a research note released on Monday morning, AnalystRatings.com reports. They currently have a $30.00 target price on the specialty pharmaceutical company’s stock.

A number of other research analysts have also recently commented on ADMS. Evercore ISI reiterated a buy rating and set a $55.00 price target on shares of Adamas Pharmaceuticals in a research report on Monday, August 12th. JMP Securities decreased their price target on shares of Adamas Pharmaceuticals to $16.00 and set an outperform rating on the stock in a research note on Friday, November 8th. Zacks Investment Research lowered shares of Adamas Pharmaceuticals from a hold rating to a sell rating in a report on Wednesday, October 16th. Bank of America cut shares of Adamas Pharmaceuticals from a neutral rating to an underperform rating and cut their price objective for the company from $9.00 to $5.00 in a research note on Monday, September 30th. Finally, Northland Securities reaffirmed a buy rating and set a $15.00 target price on shares of Adamas Pharmaceuticals in a report on Friday, November 8th. Three equities research analysts have rated the stock with a sell rating, five have issued a hold rating and five have assigned a buy rating to the company. The stock has a consensus rating of Hold and an average target price of $16.73.

ADMS opened at $6.15 on Monday. The company has a current ratio of 6.35, a quick ratio of 6.15 and a debt-to-equity ratio of 6.72. The stock has a market capitalization of $165.75 million, a P/E ratio of -1.26 and a beta of 1.77. The stock has a 50-day moving average price of $4.79 and a 200-day moving average price of $5.47. Adamas Pharmaceuticals has a 12-month low of $3.35 and a 12-month high of $12.57.

Adamas Pharmaceuticals (NASDAQ:ADMS) last announced its quarterly earnings data on Thursday, November 7th. The specialty pharmaceutical company reported ($0.99) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.90) by ($0.09). The firm had revenue of $13.93 million for the quarter, compared to analysts’ expectations of $14.36 million. Adamas Pharmaceuticals had a negative net margin of 215.09% and a negative return on equity of 205.30%. On average, equities research analysts predict that Adamas Pharmaceuticals will post -3.92 EPS for the current year.

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Stonepine Capital Management LLC lifted its position in Adamas Pharmaceuticals by 44.6% in the second quarter. Stonepine Capital Management LLC now owns 1,423,578 shares of the specialty pharmaceutical company’s stock valued at $8,826,000 after purchasing an additional 439,249 shares during the last quarter. BlackRock Inc. increased its stake in shares of Adamas Pharmaceuticals by 5.4% in the second quarter. BlackRock Inc. now owns 2,195,088 shares of the specialty pharmaceutical company’s stock worth $13,609,000 after buying an additional 112,278 shares during the period. Emerald Advisers LLC raised its holdings in Adamas Pharmaceuticals by 11.8% during the 2nd quarter. Emerald Advisers LLC now owns 700,176 shares of the specialty pharmaceutical company’s stock valued at $4,341,000 after buying an additional 73,929 shares during the last quarter. Emerald Mutual Fund Advisers Trust raised its holdings in Adamas Pharmaceuticals by 9.1% during the 2nd quarter. Emerald Mutual Fund Advisers Trust now owns 616,664 shares of the specialty pharmaceutical company’s stock valued at $3,823,000 after buying an additional 51,345 shares during the last quarter. Finally, Price T Rowe Associates Inc. MD raised its holdings in Adamas Pharmaceuticals by 366.8% during the 2nd quarter. Price T Rowe Associates Inc. MD now owns 58,797 shares of the specialty pharmaceutical company’s stock valued at $365,000 after buying an additional 46,200 shares during the last quarter. Institutional investors and hedge funds own 51.99% of the company’s stock.

About Adamas Pharmaceuticals

Adamas Pharmaceuticals, Inc focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications.

Recommended Story: What is a Fibonacci Channel?

Analyst Recommendations for Adamas Pharmaceuticals (NASDAQ:ADMS)

Receive News & Ratings for Adamas Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adamas Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.